I just have to say... I am pretty excited about where we
I just have to say... I am pretty excited about where we are right now. Of coarse I have a problem being a optimist and will probably be reminded of that.
After watching Nader’s enthusiasm yesterday and saying that revenue this year is still on the list of great things to happen for us. It’s pretty exciting. The question is... how do we get that revenue? I would like to believe our 75% interim results are powerful enough to unblind them and see where we stand. Either we are getting great results and the road heavily traveled has paid off for us and great things are in our future or we show some average amount of results and we are still saving lives and great things are in our future still. Sounds win/win to me.
Either way, we are on our way to bigger things. The first catalyst or approval will send us on our way to becoming our own pharmaceutical company with so much potential that it is hard to ignore all the possibilities. All the future revenue possibilities are mind boggling.
I invested here with one indication in mind and that was HIV and things have changed dramatically since then with all the possible indications that are possible. I had no idea there would be such a drug like Leronlimab or should I say Virologix.
Getting our first approval speeds up the process of how we go about trialing the other indications and there is so many and that is huge potential.
The old saying is... It takes money to make money. That really holds true as a fledgling pharmaceutical company. Once we can afford to go full tilt on other trials for the top 10 indications for saving lives. The further and faster we will ascend. Luckily the top 10 indications are the highest revenue indications. Saving lives is big money. Our future is so bright... I am wearing my sunglasses at night. To quote I believe Cory Hart. For those old rockers. It’s fun to think we are almost there. We are not out of the woods yet but soon... very soon I think. Good times are just around the corner.
7
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...
Continue Reading
What's Fueling the Market's Climb? I tell ya, sodium silicate might not be a household name, but it's trekking upwards with a clear purpose. By 2031, this market's expected to touch $7.4 billion from $6 billion in 2026 at a neat 4.4% CAGR. For an old-school trader like me, that's the kind of steady growth that catches my eye. The driving factors? Well, it’s more than...
Continue Reading
Navigating College Choices: More Than Just a Hunch When it comes to picking the right college, a lot of folks think it's like shooting in the dark—it's more than just a blind dart throw at a life map. According to a new report from the College Board, aligning with the right academic institution isn't merely a nice-to-have deal; it fundamentally shifts the odds in favor...
Continue Reading
Wine Industry Shifts Gears Well, here's a twist that might just shake up the wine racks. C. Mondavi & Family, from the historic Charles Krug estate, is aligning with Missing Thorn—a name gaining traction in the non-alcoholic wine scene. It’s a move that not only raises eyebrows but could also expand your wine-tasting options come your next sober night out. So what...
Continue Reading
More Than Just a Debt Guru It's not every day you see a former NFL player shifting gears so smoothly into the corporate world, and then to community service like a missile lock. But that's exactly what Don Silvestri, president of Debt.com, has done. Dragging a hefty reputation as a placekicker for teams like the New York Jets and the Buffalo Bills, he's now making...
Continue Reading
Shaking Up the Global Hiring Playbook You think you know how hiring works globally? Think again. Based on data from a whopping 38,000 cross-border hires, Multiplier's latest Talent Trends has spilled some hot new beans on how companies are rethinking their talent acquisition strategies. This isn’t just some thumb-twiddling speculation either—it’s grounded in real...
Continue Reading
Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...
Continue Reading
Untangling the Surge in Infection Control Demand Lately, it's like every healthcare joint worldwide is scrambling for better infection control. We're talking about a market poised to jump from a whopping USD 58.5 billion in 2026 to USD 80.2 billion by 2031—a tidy 37% uptick. That change, brewing at a 6.5% CAGR, speaks volumes about where the industry's heading. What's...
Continue Reading
An Unexpected Shuffle at the Ad Council Alright, folks, let's talk shop about the recent shake-up in the nonprofit realm. The Ad Council, which has been around longer than some of the giants controlling today's marketing landscapes, just plumped up its Board of Directors with 23 new heavy-hitters. We're talking about leaders from every nook and cranny of the...
Continue Reading
Why Life Changes Demand an Insurance Review The nitty-gritty of life doesn't sit still—marriages, babies, job changes, and home deals or steals each bring their own clutter to the table. One thing's for sure: when your life shifts, your insurance ought to keep pace. Insurance Agent Nick Hogan drops the dime in the latest HelloNation article, laying it bare why...
Continue Reading